tbuckley/cabot-search huggingface dataset:
Change in Source of Information: Availability of Varicella Vaccine for Children With Acute Lymphocytic Leukemia
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Spiral Fracture
Authors: Otto E. Aufranc
Journal: JAMA (1961)

<h3>To the Editor:—</h3> I was happy to see that there was interest in our Fracture of the Month. It was hoped that we would get comments from those interested in fractures. I agree with the correspondent that no fracture is ever an oblique fracture. This is a poor habit of speaking which I am sure most of us get into by looking at the x-rays. I agree thoroughly that all fractures of this sort are spiral oblique in nature and not only oblique. If these discussions do nothing else other than purify our language and our manner of discussing these cases, they will have accomplished a great deal.
Characterization of <i>KRAS, NRAS, </i>and <i>BRAF </i>testing and timing among mCRC patients treated at community cancer centers in the United States.
Authors: Kimberly Lowe, Michael Anthony Kelsh, Kevin McCarl, Gerry C. Bohac
Journal: Journal of Clinical Oncology (2016)

695 Background: The requirement to establish RAS status prior to administration of an EGFR inhibitor has increased the need to understand which patients are tested for RAS and the length of time it takes for the treating oncologist to receive the RAS test result. Our objective was to evaluate factors that may influence RAS testing among patients with metastatic colorectal cancer (mCRC) and the turn-around time for RAS testing among patients who are treated at community cancer centers in the United States (U.S.). Methods: The sample includes 1550 patients in the Oncology Services Comprehensive Electronic Records (OSCER) database who were diagnosed with mCRC between 1/1/2011 and 8/31/2015. Patient demographics and clinical characteristics were evaluated at the time of mCRC diagnosis. The median number of days and interquartile range (IQR) between the following dates was summarized: diagnosis for mCRC, tissue collection for biomarker testing, tissue was received by the lab for biomarker testing, and biomarker results returned to the oncologist. Results: The frequency of RAS testing was as follows: KRAS (n = 964; 62%), NRAS (n = 116; 7%), BRAF (n = 231; 15%), all three simultaneously (n = 94, 6%). There were significant differences in KRAS testing by age and type of insurance, with young (p &lt; 0.001) and commercially-insured (p = 0.01) patients more likely to receive testing. The median number of days and IQR between specimen collection and diagnosis of mCRC was as follows: KRAS (0; 0 to 443), NRAS (0; -18.5 to 362), and BRAF (-3; -474 to 0). The median number of calendar days between the date the specimen was collected and the date it was received by the lab was as follows: KRAS (19; 1 to 303), NRAS (34.5, 8 to 518), and BRAF (29; 2 to 428). The median number of days between the date the specimen was received by the lab and the date the result was returned to the oncologist was as follows: KRAS (7; 5 to 13), NRAS (10; 7 to 15), and BRAF (8; 6 to 14). Conclusions: Many patients had a specimen collected for biomarker testing at the time of mCRC diagnosis and the results were generally returned to the treating oncologist within one week of it arriving at the lab.
Oral Anatomy
Authors: John R. Thompson
Journal: JAMA (1960)

In his introductory remarks the author strikes at the core of the major problem in dental and medical education—the correlation of basic scientific knowledge and clinical practice. In this third edition the ultimate success has been achieved, as far as can be in the written word, in making this correlation realistic. The author says, "This book tries to bridge the gap between theory and practice and to prove that anatomic understanding does not only facilitate clinical work but that it also allows for the substitution of a rigid clinical technique by an adaptable and therefore potentially progressive action." The book is divided into two parts. The first is concerned primarily with the descriptive anatomy of the head and neck. It also includes a comprehensive discussion of head growth and tooth eruption which is essential to logical analysis and treatment of clinical conditions. This section has been expanded to include knowledge
ESGE Newsletter
Journal: Endoscopy (2014)

Under the leadership of Cesare Hassan, Italy, ESGE is dedicated to producing guidelines, also at times in cooperation with sister societies. In 2014, five guidelines appeared in Endoscopy and several working groups are preparing new guidelines and updating standing recommendations. The most recent working group meeting was held in Berlin, where experts convened to take forward the guideline on Non Variceal Upper GI Bleeding under the leadership of Professor Gralnek.
Essential Urology
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Diseases of War
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DISSIMILAR EYES.
Authors: NORBURNE B. JENKINS
Journal: JAMA (1899)

Many persons have considerable difference in the size and conformation of the eyes. The external measurements of one eye may differ from those of the other. One eye only may be perfect. Both eyes may be imperfectly formed, the imperfection of one eye differing in degree or in nature from that of its fellow. The combinations met with are numerous and varied. Occasionally one eye sees distinctly only distant objects, while the other is of service only for near vision. Often one eye is used for both near and distant vision, the other eye being used but little or not at all. A considerable difference sometimes exists until late in life without affecting the vision or comfort. On the other hand, slight differences frequently cause strabismus, amblyopia and asthenopia early in life. The above condition is called ''anisometropia.'' The reasons advanced for the frequent failures to correct it with lenses
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Authors: J Mcmurray, S Solomon, S Inzucchi, L Køber, M Kosiborod, F Martinez, P Ponikowski, I Sabatine, J Anand, M Bělohlávek, C.-E Böhm, V Chiang, R Chopra, A De Boer, M Desai, J Diez, A Drozdz, J Dukát, J Ge, T Howlett, M Katova, C Kitakaze, B Ljungman, J Merkely, E Nicolau, M O'meara, P Petrie, M Vinh, S Schou, S Tereshchenko
Journal: New England Journal of Medicine (2020)

In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucoseindependent mechanisms.More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. METHODSIn this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy.The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. RESULTSOver a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001).A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83).Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97).Findings in patients with diabetes were similar to those in patients without diabetes.The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups. CONCLUSIONSAmong patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.
A neonatal inflating-bag.
Authors: W Mushin
Journal: BMJ (1967)

Today's Drugs adequate.When, however, iron deficiency anaemia is present in early pregnancy at least three such tablets should be given daily.All the iron preparations listed below are probably equally satisfactory.These tablets should be given combined with folic acid.The observations of Rybo in Gothenburg3 and of Chanarin, Rothman, and Ward in London4 indicate that 100 /,Lg.folate daily maintains a normal red-cell folate throughout pregnancy when this is given with supplemental iron.Patients in poor social and economic circumstances and whose diet is likely to be poor should probably receive a larger amount and their requirement could be met by two such tablets each day.In practice most of the available preparations contain ade- quate quantities of iron and more than adequate quantities of folate.This generous provision of folate is probably not of great consequence.These preparations are listed in Table II.
Polycythemia vera treated with recombinant interferon‐alpha 2a: Evidence of a selective effect on the malignant clone
Authors: Paolo Massaro, Paolo Foa, Mauro Pomati, Maria Luisa LaTargia, Alessandra Iurlo, Claudia Clerici, Sarah Caldiera, Monica Fornier, Anna Teresa Maiolo
Journal: American Journal of Hematology (1997)

We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferon-alpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations, while 2 displayed at diagnosis the presence of trisomy 8 in all bone-marrow metaphases. Interestingly enough, in these 2 patients rIFN-alpha treatment was able to induce not only complete hematological response but also the disappearance of trisomy 8, as shown by conventional cytogenetic investigation and fluorescence in situ hybridization performed on bone-marrow cells after 1 year of treatment. This finding indicates that, as previously shown in chronic myeloid leukemia, in PV rIFN-alpha can also eradicate the malignant clone by means of a selective effect on bone-marrow transformed cells. Am. J. Hematol. 56:126–128, 1997. © 1997 Wiley-Liss, Inc.
Varicella arthritis
Authors: J. R. Ward
Journal: JAMA (1970)

Typical chicken pox presented with arthritis in the left knee in a 5-year-old girl. Attempts to isolate bacteria, Mycoplasma, and viruses were unsuccessful. The arthritis subsided promptly and long term follow-up has failed to yield evidence of other disease. Varicella virus infection may be the cause of the arthritis.
Reproductive Toxicity of Ethylene Glycol Monoethyl Ether Tested by Continuous Breeding of CD-1 Mice
Authors: James C. Lamb, Dushyant K. Gulati, Valerie S. Russell, Leta Hommel, Pritam S. Sabharwal
Journal: Environmental Health Perspectives (1984)

The reproductive toxicity of ethylene glycol monoethyl ether (EGEE) was evaluated in the Fertility Assessment by Continuous Breeding protocol. Both male and female CD-1 mice were given 0, 0.5, 1.0 or 2% EGEE in the drinking water and were housed as breeding pairs continuously for 14 weeks. Significant adverse effects on fertility were seen at 1 and 2% but not at 0.5%. After the continuous breeding phase of this test was completed, treated males were housed with control females and treated females with control males and fertility and reproduction were compared to the corresponding pairs of control male and control female mice. Both males and females from the 1 and 2% groups were affected. Testicular atrophy, decreased sperm motility and increased abnormal sperm were noted in the treated males, but no specific anomalies were detected in the females.
Villous adenoma of rectosigmoid accompanied by electrolyte depletion
Authors: S. S. Solomon
Journal: JAMA (1965)

Villous adenoma of the rectosigmoid causing debilitating water and electrolyte loss is being recognized with increasing frequency in the geriatric population. Watery diarrhea, extreme weakness, dehydration, and renal insufficiency are virtually constant findings; a variety of bizarre accompanying symptoms frequently accounts for delayed or erroneous diagnosis. These bulky lesions may be elusive to physical diagnosis because of the mobility and soft texture of tumor fronds. Rectal losses are hypertonic with respect to potassium, and hypokalemic nephropathy is probably the basis for renal insufficiency in this condition. Accurate assessment and replacement of rectal losses, combined with early surgery, is the crux of successful management. Because adequate biopsy is difficult, because invasive carcinoma occurs in 25% of cases, and because inadequate local therapy is often followed by tumor recurrence and continuing losses, surgical resection along limits acceptable for malignancy is recommended.
An International Sanitary Conference.
Journal: JAMA (1885)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatic tumours in childhood.
Journal: BMJ (1972)

pointed its "general" ombudsman in 1969 he was empowered to investigate complain;ts in the N.H.S., but his area of activity was strictly confined to administration and both the Government and profession agreed on a definition to achieve this demarcation.8A similar formula will be needed in England and Wales, because it is vital that the Health Commissioner should not investigate actions based on clini- cal judgement.Patients already have well tried remedies through the courts for dealing with dissatisfaction over medical treatment given by general practitioners or hospital staff.Litigation against doctors in the U.S.A. has already reached alarming proportions, fortunately not yet matched in Britain, though even here the increase is worrying.Patients must not regard the ombudsman as a possible dry run for a court case against a doctor, and some agreement between the B.M.A. and the Government should be worked out to preclude this.Second thoughts about the ombudsman's title might help to underline his function of investigating maladministration-a word which itself needs to be clearly defined.Perhaps the Government should consider calling him a Commissioner for N.H.S. Administration.To many patients the N.H.S., particularly its hospitals, may appear frighteningly large and mysterious.If an om- budsman can lessen their worries and improve their confi- dence in the Service he will have achieved something.But if his activities prompt doctors, nurses, and other N.H.S. workers to look increasingly over their shoulders before carrying out treatment, then this new institution would do both patients and staff a grave disservice.
From the Centers for Disease Control. Transmission of HIV possibly associated with exposure of mucous membrane to contaminated blood
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Progress toward achieving the national 1990 objectives for immunization
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PENETRATION OF THE INTESTINE BY ENDAMEBA HISTOLYTICA
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal